Neoplasms, Plasma Cell: all 2,314 studies
Page 21 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma PatientsStatus unknownNCT00382694Phase 2
- Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple MyelomaCompletedNCT00378768Phase 2
- Autologous Transplantation for Multiple MyelomaCompletedNCT00378222Phase 3
- Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other DiseasesCompletedNCT00376922Not applicable
- Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/MonthCompletedNCT00376883Phase 3
- Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic DiseasesTerminatedNCT00376519Phase 1
- Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple MyelomaCompletedNCT00375791Phase 2
- CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell TransplantTerminatedNCT00369291Phase 1
- EMMA-1 (Erbitux for Multiple Myeloma)TerminatedNCT00368121Phase 2
- Treatment of Newly Diagnosed Elderly Patients With Multiple MyelomaCompletedNCT00367185Phase 3
- Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney CancerCompletedNCT00365287Phase 1/2
- A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple MyelomaTerminatedNCT00361088Phase 1/2
- Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma PatientsCompletedNCT00358020Phase 2
- A Study of ATN-224 and Bortezomib in Patients With Multiple MyelomaTerminatedNCT00352742Phase 1/2
- TCD Followed by autoSCT for Newly Diagnosed MM PatientsStatus unknownNCT00349115Phase 2
- BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT00346255Phase 1
- Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00344422Phase 3
- Genome Expression in Lymphoma, Leukemia and Multiple MyelomaCompletedNCT00339963
- Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaTerminatedNCT00337506Phase 2
- Fluphenazine in Treating Patients With Refractory Advanced Multiple MyelomaCompletedNCT00335647Phase 1/2
- Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma RelapseCompletedNCT00335348Phase 2
- Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple MyelomaStatus unknownNCT00334932Phase 1/2
- Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple MyelomaStatus unknownNCT00327314Phase 2
- Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma PatientsCompletedNCT00327249Phase 1/2
- Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantTerminatedNCT00324324Phase 3
- A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple MyelomaCompletedNCT00323505Phase 2
- VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant CandidatesCompletedNCT00320476Phase 2
- PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple MyelomaStatus unknownNCT00319865Phase 2
- Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00317811Phase 2
- Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple MyelomaCompletedNCT00317798Phase 1
- Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00316940Phase 1
- Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT00315757Phase 2
- Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple MyelomaCompletedNCT00313625Phase 2
- VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)Status unknownNCT00311337Phase 2
- Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00310024Phase 1
- Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00306813Phase 1/2
- Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.CompletedNCT00306735Phase 2
- Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple MyelomaCompletedNCT00305812Phase 2
- Study of XL999 in Patients With Multiple MyelomaTerminatedNCT00304590Phase 2
- Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00304018Phase 1
- Sorafenib and Bortezomib in Treating Patients With Advanced CancerCompletedNCT00303797Phase 1
- Study of ZIO-101 in Multiple MyelomaCompletedNCT00303199Phase 1/2
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic CancerCompletedNCT00301951Phase 1
- Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00301912Phase 2
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerCompletedNCT00296023Not applicable
- Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic AnemiaStatus unknownNCT00295997Not applicable
- Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)TerminatedNCT00293111Phase 2
- Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple MyelomaCompletedNCT00291538Phase 1
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerTerminatedNCT00290628Not applicable
- Quality of Life in Patients With Multiple MyelomaCompletedNCT00290095
- Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell TransplantCompletedNCT00288028Phase 1
- Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow TransplantCompletedNCT00281814
- Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow TransplantationCompletedNCT00281801
- The Effect of High Dose Simvastatine on Multiple MyelomaCompletedNCT00281476Phase 1/2
- Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or MyelomaCompletedNCT00276536Phase 1
- The Effect of Epoetin Alfa on the Anemia of Patients With Multiple MyelomaCompletedNCT00270101Phase 3
- Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerCompletedNCT00265837Phase 3
- Higher Frequency Zoledronic Acid in the Treatment of Multiple MyelomaCompletedNCT00263484Phase 2
- Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell DisordersTerminatedNCT00258258Phase 1
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT00258245Phase 1
- Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and TolerabilityCompletedNCT00257114Phase 4
- Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for CancerCompletedNCT00255749Phase 2
- Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic CancerCompletedNCT00255710Phase 1
- Sorafenib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00253578Phase 2
- G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic DisordersTerminatedNCT00253552Not applicable
- Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid CancerCompletedNCT00248430Phase 1/2
- TKI258 in Subjects With Refractory or Relapsed Multiple MyelomaTerminatedNCT00243763Phase 1
- Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00243035Phase 1/2
- Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple MyelomaTerminatedNCT00242827Phase 2
- Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.WithdrawnNCT00242528Phase 4
- A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00241371Phase 2
- Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast CancerCompletedNCT00237627Phase 1/2
- A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF AloneCompletedNCT00234169Phase 1/2
- Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma PatientsCompletedNCT00232934Phase 3
- Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple MyelomaCompletedNCT00231166Phase 1
- Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00227682Phase 2
- IFM 99-02 Thalidomide in MyelomaCompletedNCT00222053Phase 3
- Thalidomide to Patients With Previously Untreated Multiple MyelomaCompletedNCT00218855Phase 3
- An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib TherapyCompletedNCT00216697Phase 2
- Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple MyelomaTerminatedNCT00216151Phase 2
- The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple MyelomaCompletedNCT00207805Phase 3
- Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance TherapyCompletedNCT00205764Phase 3
- Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple MyelomaCompletedNCT00201695Phase 2
- IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple MyelomaCompletedNCT00200681Phase 3
- Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.TerminatedNCT00200668Not applicable
- Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple MyelomaCompletedNCT00193557Phase 2
- Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple MyelomaCompletedNCT00193544Phase 2
- Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic CellsCompletedNCT00186316Phase 1/2
- High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple MyelomaCompletedNCT00186238Phase 2
- Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple MyelomaCompletedNCT00185653Not applicable
- Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With TransplantCompletedNCT00182663Phase 2
- Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative DiseaseTerminatedNCT00176475Phase 1
- Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple MyelomaStatus unknownNCT00166855Not applicable
- Protein Tyrosine Kinases (PTK) in Multiple MyelomaCompletedNCT00165347Phase 2
- Atorvastatin in MyelomaStatus unknownNCT00164086Phase 1
- Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple MyelomaCompletedNCT00151203Phase 2
- Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the BloodCompletedNCT00146055Phase 2
- Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple MyelomaCompletedNCT00135187Not applicable
- Clinical Trial of PXD101 in Patients With Advanced Multiple MyelomaCompletedNCT00131261Phase 2
- Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple MyelomaStatus unknownNCT00124813Phase 2